Haemonetics director awarded 2,538 RSUs
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Zane Ellen M reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corporation director Ellen M. Zane received a grant of 2,538 restricted stock units under the company’s Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, and her direct common stock holdings total 21,911 shares after the award.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 2,538 | -- | -- |
Footnotes (2)
- F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
- F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Key Figures
Key Terms
restricted stock units financial
contingent right financial
Long-Term Incentive Compensation Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Haemonetics (HAE) director Ellen M. Zane report?
How many restricted stock units did Ellen M. Zane receive from Haemonetics (HAE)?
When do Ellen M. Zane’s Haemonetics (HAE) restricted stock units vest?
What does each RSU granted to Ellen M. Zane at Haemonetics (HAE) represent?
AI-generated analysis. How Rhea-AI works. Not financial advice.